COVID-19 vaccine short-term adverse events in the real-life family practice in Krakow, Poland

Abstract Background In manufacturers’ trials, vaccination against COVID-19 proved to be safe and effective. The officially reported frequency of vaccine adverse events (VAEs) in Poland is lower than that declared by the manufacturers. The anti-vaccination activists questioned the trustworthiness of official data. Objectives The aim was to explore the real-life prevalence of VAEs in general practice settings and the factors that may influence it. Methods In this pragmatic, mixed prospective and retrospective study, patients vaccinated against COVID-19 between May and October 2021 in three GP practices in Krakow, Poland, were enrolled. Their demographic (age, sex, level of education) and clinical data (weight and height, smoking status, history of allergies, COVID-19 and chronic diseases) were collected. Then, they were interviewed about VAEs they experienced. Results Out of 1530 patients invited to participate, 1051 (69%) agreed and were eligible for analyses. Only 8.8% did not report any VAE. Pain at the injection site was the most frequently reported reaction (800, 76.2%). The most prevalent systemic ones were excessive fatigue/lethargy (527, 50.6%), sleep/circadian rhythm disturbances (433, 41.6%) and headache (399, 38.3%). Fifty required medical assistance − 39 experienced presyncope (3.7%) and 11 loss of consciousness (1.1%). Only two others were hospitalised. Females, younger adults, those with higher education and with a history of COVID-19 reported systemic VAEs more frequently, while those who were older and obese were less likely to report local reactions. Conclusion Although more than 90% of patients vaccinated against COVID-19 in general practice settings may experience VAEs, in short-term observation, the vast majority are localised and mild.

[1]  Kristine Macartney,et al.  The short term safety of COVID‐19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021 , 2022, The Medical journal of Australia.

[2]  K. Überla,et al.  Active monitoring of adverse reactions following COVID-19 and other vaccinations: a feasibility study as part of the CoVaKo project , 2022, Pilot and Feasibility Studies.

[3]  Ana Isabel Beltrán-Velasco,et al.  Mis–Dis Information in COVID-19 Health Crisis: A Narrative Review , 2022, International journal of environmental research and public health.

[4]  Kirby Goidel,et al.  Imperfect messengers? An analysis of vaccine confidence among primary care physicians , 2022, Vaccine.

[5]  M. Michalak,et al.  Safety Profile of COVID-19 Vaccines among Healthcare Workers in Poland , 2022, Vaccines.

[6]  E. Isomura,et al.  Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: a cross-sectional study , 2022, BMC Infectious Diseases.

[7]  Colin Simpson,et al.  Investigating the uptake, effectiveness and safety of COVID-19 vaccines: protocol for an observational study using linked UK national data , 2022, BMJ Open.

[8]  Sameh Attia,et al.  Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central Europe , 2021, Journal of clinical medicine.

[9]  L. Moreno,et al.  Association between COVID-19 Vaccine Side Effects and Body Mass Index in Spain , 2021, Vaccines.

[10]  Paige G. Wickner,et al.  Association of Self-reported High-Risk Allergy History With Allergy Symptoms After COVID-19 Vaccination , 2021, JAMA network open.

[11]  J. MacKillop,et al.  COVID-19 Vaccine Perceptions and Differences by Sex, Age, and Education in 1,367 Community Adults in Ontario , 2021, Frontiers in Public Health.

[12]  A. Wojtczak,et al.  Vaccination against COVID-19 in Poland , 2021, Journal of Education, Health and Sport.

[13]  Xinghui Chen,et al.  Evaluation of the safety profile of COVID-19 vaccines: a rapid review , 2021, BMC Medicine.

[14]  C. Chirouze,et al.  Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine , 2021, Vaccine.

[15]  H. Zou,et al.  Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials , 2021, Infectious Diseases of Poverty.

[16]  S. Andrzejczak-Grządko,et al.  Side effects after COVID-19 vaccinations among residents of Poland. , 2021, European review for medical and pharmacological sciences.

[17]  A. Szeląg,et al.  The Incidence and Severity of Post-Vaccination Reactions after Vaccination against COVID-19 , 2021, Vaccines.

[18]  A. Hapfelmeier,et al.  The diversity of opinion among general practitioners regarding the threat and measures against COVID-19 – Cross-sectional survey , 2021, The European journal of general practice.

[19]  W. Cullen,et al.  COVID-19’s impact on primary care and related mitigation strategies: A scoping review , 2021, The European journal of general practice.

[20]  A. Neves,et al.  Virtual primary care in high-income countries during the COVID-19 pandemic: Policy responses and lessons for the future , 2021, The European journal of general practice.

[21]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[22]  A. Windak,et al.  Academic general practice/family medicine in times of COVID-19 – Perspective of WONCA Europe , 2020, The European journal of general practice.